Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30891068 | 1.00 | ALDH1A1 (0.32) | ALDH1A1ALOX15TSHRNPSR1 | |
| SCHEMBL16446289 | 0.84 | ALDH1A1 (0.32) | ALDH1A1ALOX15TSHRNPSR1 | |
| SCHEMBL7981865 | 0.82 | ALDH1A1 (0.41) | ALDH1A1ALOX15TSHR | |
| SCHEMBL15201046 | 0.81 | CYP1A2 (0.36) | ALDH1A1ALOX15TSHRNPSR1 | |
| SCHEMBL12330649 | 0.79 | ALDH1A1 (0.30) | ALDH1A1ALOX15TSHRNPSR1 | |
| SCHEMBL12575818 | 0.79 | DPP4 (0.33) | ALDH1A1ALOX15TSHRNPSR1 | |
| SCHEMBL30891109 | 0.79 | ALDH1A1 (0.30) | ALDH1A1ALOX15TSHRNPSR1 | |
| SCHEMBL4980998 | 0.77 | ALDH1A1 (0.39) | ALDH1A1 | |
| SCHEMBL649969 | 0.76 | TLR8 (0.39) | ALDH1A1NPSR1 | |
| SCHEMBL22120057 | 0.74 | CYP1A2 (0.39) | NPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 52 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024044731-A1 | DIAZEPINO-THIENO-QUINOXALINE COMPOUNDS AND THEIR USE IN THERAPY | MATCHPOINT THERAPEUTICS INC. (US) | 2024-02-29 | — | — | WO | disclosed |
| WO-2024044731-A1 | DIAZEPINO-THIENO-QUINOXALINE COMPOUNDS AND THEIR USE IN THERAPY | MATCHPOINT THERAPEUTICS INC. (US) | 2024-02-29 | — | — | WO | disclosed |
| US-9359349-B2 | Substituted quinazolines as kinase inhibitors | INTELLIKINE LLC (US) | 2016-06-07 | — | — | US | disclosed |
| US-9359349-B2 | Substituted quinazolines as kinase inhibitors | INTELLIKINE LLC (US) | 2016-06-07 | — | — | US | disclosed |
| US-20150141442-A1 | CHEMICAL ENTITIES AND THERAPEUTIC USES THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-05-21 | — | — | US | disclosed |
| US-20150141442-A1 | CHEMICAL ENTITIES AND THERAPEUTIC USES THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-05-21 | — | — | US | disclosed |
| US-20140350248-A1 | CHEMICAL ENTITIES AND THERAPEUTIC USES THEREOF | Intellikine, LLC. (US) | 2014-11-27 | — | — | US | disclosed |
| US-20140350248-A1 | CHEMICAL ENTITIES AND THERAPEUTIC USES THEREOF | Intellikine, LLC. (US) | 2014-11-27 | — | — | US | disclosed |
| US-8129395-B2 | 4,5-disubstituted-2-aryl pyrimidines | NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) | 2012-03-06 | — | — | US | disclosed |
| US-8129395-B2 | 4,5-disubstituted-2-aryl pyrimidines | NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) | 2012-03-06 | — | — | US | disclosed |
| US-4283331-A | FIBER-REACTIVE DYES | CIBA-GEIGY CORPORATION (US) | 1981-08-11 | — | — | US | disclosed |
| US-4210582-A | FIBER-REACTIVE YELLOW DYES FOR WOOL | CIBA-GEIGY CORPORATION (US) | 1980-07-01 | — | — | US | disclosed |
| US-4141890-A | FIBER-REACTIVE | CIBA-GEIGY CORPORATION (US) | 1979-02-27 | — | — | US | disclosed |
| US-4067864-A | FOR CELLULOSE OR POLYAMIDES | CIBA-GEIGY AG (CH) | 1978-01-10 | — | — | US | disclosed |
| US-4039523-A | YELLOW | CIBA-GEIGY AG (CH) | 1977-08-02 | — | — | US | disclosed |
| US-4017477-A | 3-Halogeno-6-hydroxy-pyridone-(2) azo dyestuffs | CIBA-GEIGY AG (CH) | 1977-04-12 | — | — | US | disclosed |
| US-4001203-A | Heavy metal complexes of azo dyestuffs containing a heterocyclic diazo component and the residue of 5-halogeno-2,3-dihydrozypyridine as coupling component | CIBA-GEIGY AG (CH) | 1977-01-04 | — | — | US | disclosed |
| US-4001205-A | WATER-SOLUBLE, FIBER-REACTIVE PHENYLAZODIHYDROXY, METHYL, CYANOPYRIDINE DYESTUFFS | CIBA-GEIGY AG (CH) | 1977-01-04 | — | — | US | disclosed |
| US-3971738-A | Heavy metal complexes of azo compounds containing a halogeno-2,3-dihydroxy pyridine coupling component | CIBA-GEIGY AG (CH) | 1976-07-27 | — | — | US | disclosed |
| US-3956263-A | 4-Methyl-2,6-dihydroxy-3-cyanopyridine containing dyestuffs | CIBA-GEIGY AG (CH) | 1976-05-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140350248-A1 | CHEMICAL ENTITIES AND THERAPEUTIC USES THEREOF | PIK3CA, PIK3CB, PIK3C3 | ALDH1A1 2519/4885ALOX15 3382/4885TSHR 4172/4885 |
| US-20150141442-A1 | CHEMICAL ENTITIES AND THERAPEUTIC USES THEREOF | PIK3CA, PIK3CB, PIK3C3 | ALDH1A1 2519/4885ALOX15 3382/4885TSHR 4172/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.